NextCure (NXTC) Research Hub

NextCure (NXTC) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-10-26, shares last closed at 5.23 USD (+5.02%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -0.23, market cap 0.01B. This hub links to the full technical, earnings and options research available for NXTC.

Last updated 2026-10-26 · Source: end-of-day prices (adjusted); indicators computed by SniperIQ

SectorHealthcare (Biotechnology)
ExchangeNASDAQ, US
Last close5.23 USD (+5.02%)
52-week range1.55 USD – 8.66 USD
Trend regimeRange
14-day RSI45.9 (Neutral)
Trailing P/E-0.23
Market cap0.01B
Dividend yield0.00%
Next earnings2026-08-06

Available research for NXTC

Earnings

NXTC earnings date and last-quarter result: next report 2026-08-06, last quarter miss, P/E -0.23. Updated 2026-07-23.

Options: Covered Call

Covered Call on NXTC: how it works, illustrative setup around the real 5.23 USD price, max profit/loss, breakeven and when to use it. Educational.

Options: Iron Condor

Iron Condor on NXTC: how it works, illustrative setup around the real 5.23 USD price, max profit/loss, breakeven and when to use it. Educational.

Options: Protective Put

Protective Put on NXTC: how it works, illustrative setup around the real 5.23 USD price, max profit/loss, breakeven and when to use it. Educational.

Technical

NXTC technical analysis: range, last 5.23 USD, RSI 45.9, 52w range 1.55 USD–8.66 USD, real support/resistance. Updated 2026-10-26.

More on SniperIQ

Frequently asked questions

What sector is NXTC in?

NextCure (NXTC) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.

Is NXTC in an uptrend or downtrend?

As of 2026-10-26, NXTC is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.

What is NXTC's trailing P/E ratio?

NXTC's trailing P/E is -0.23, with a market cap of 0.01B. See the earnings research page for full valuation detail.

When does NXTC next report earnings?

NXTC is next scheduled to report earnings on 2026-08-06.